Jazz Pharmaceuticals price target lowered to $165 from $166 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $165 from $166 and keeps an Overweight rating on the shares. The firm, which sees several factors that should lead to a stronger Q2 after a “meaningful miss” on revenue in Q1, sees Jazz as likely entering a key inflection point in the second half with major clinical catalysts, the analyst tells investors in a preview.